Brandon M L
Ann Allergy. 1978 Feb;40(2):86-93.
In a parallel-group, double-blind study 28 chronic asthmatic patients were treated for 90 days with metered dose inhalers of fenoterol and isoproterenol, at daily doses of 0.4 mg t.i.d. and 0.15 mg t.i.d., respectively. Fenoterol produced significant improvements in FEV1 and FEF25-75%, greater than those achieved with isoproterenol, in tests on days 1, 45 and 90; its median duration of action was two to four times longer than that of isoproterenol. Ratings for overall responses to treatment were higher for fenoterol and mean attack rates showed a greater decline than with isoproterenol.
在一项平行组双盲研究中，28名慢性哮喘患者分别使用非诺特罗和异丙肾上腺素定量吸入器治疗90天，剂量分别为每日0.4毫克，每日三次和每日0.15毫克，每日三次。在第1、45和90天的测试中，非诺特罗使第一秒用力呼气量（FEV1）和用力呼气中期流速（FEF25 - 75%）有显著改善，优于异丙肾上腺素；其平均作用持续时间比异丙肾上腺素长两到四倍。非诺特罗的总体治疗反应评分更高，平均发作率下降幅度比异丙肾上腺素更大。
